Ultra-high field proton MR spectroscopy in early-stage amyotrophic lateral sclerosis

I Cheong, M Marjańska, DK Deelchand… - Neurochemical …, 2017 - Springer
A major hurdle in the development of effective treatments for amyotrophic lateral sclerosis
(ALS) has been the lack of robust biomarkers for use as clinical trial endpoints …
被引用次数：49 相关文章

[引用][C] Ultra-High Field Proton MR Spectroscopy in Early-Stage Amyotrophic Lateral Sclerosis

I Cheong, M Marjańska, DK Deelchand… - Neurochemical …, 2017 - cir.nii.ac.jp
Ultra-High Field Proton MR Spectroscopy in Early-Stage Amyotrophic Lateral Sclerosis | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …

Ultra-High Field Proton MR Spectroscopy in Early-Stage Amyotrophic Lateral Sclerosis.

I Cheong, M Marjańska, D Deelchand… - Neurochemical …, 2017 - search.ebscohost.com
A major hurdle in the development of effective treatments for amyotrophic lateral sclerosis
(ALS) has been the lack of robust biomarkers for use as clinical trial endpoints …
[HTML] nih.gov

[HTML][HTML] ULTRA-HIGH FIELD PROTON MR SPECTROSCOPY IN EARLY-STAGE AMYOTROPHIC LATERAL SCLEROSIS

I Cheong, M Marjańska, DK Deelchand… - Neurochemical …, 2017 - ncbi.nlm.nih.gov
A major hurdle in the development of effective treatments for amyotrophic lateral sclerosis
(ALS) has been the lack of robust biomarkers for use as clinical trial endpoints …

Ultra-High Field Proton MR Spectroscopy in Early-Stage Amyotrophic Lateral Sclerosis

I Cheong, M Marjańska, DK Deelchand… - Neurochemical …, 2017 - experts.umn.edu
A major hurdle in the development of effective treatments for amyotrophic lateral sclerosis
(ALS) has been the lack of robust biomarkers for use as clinical trial endpoints …

Ultra-High Field Proton MR Spectroscopy in Early-Stage Amyotrophic Lateral Sclerosis

I Cheong, M Marjaska, DK Deelchand… - Neurochemical …, 2017 - search.proquest.com
A major hurdle in the development of effective treatments for amyotrophic lateral sclerosis
(ALS) has been the lack of robust biomarkers for use as clinical trial endpoints …

Ultra-High Field Proton MR Spectroscopy in Early-Stage Amyotrophic Lateral Sclerosis

I Cheong, M Marjańska… - Neurochemical …, 2017 - pubmed.ncbi.nlm.nih.gov
A major hurdle in the development of effective treatments for amyotrophic lateral sclerosis
(ALS) has been the lack of robust biomarkers for use as clinical trial endpoints …

Ultra-High Field Proton MR Spectroscopy in Early-Stage Amyotrophic Lateral Sclerosis.

I Cheong, M Marjańska, DK Deelchand… - Neurochemical …, 2017 - europepmc.org
A major hurdle in the development of effective treatments for amyotrophic lateral sclerosis
(ALS) has been the lack of robust biomarkers for use as clinical trial endpoints …

Ultra-High Field Proton MR Spectroscopy in Early-Stage Amyotrophic Lateral Sclerosis

I Cheong, M Marjańska, DK Deelchand… - Neurochemical …, 2017 - infona.pl
A major hurdle in the development of effective treatments for amyotrophic lateral sclerosis
(ALS) has been the lack of robust biomarkers for use as clinical trial endpoints …

Ultra-High Field Proton MR Spectroscopy in Early-Stage Amyotrophic Lateral Sclerosis.

I Cheong, M Marjańska, DK Deelchand… - Neurochemical …, 2017 - europepmc.org
A major hurdle in the development of effective treatments for amyotrophic lateral sclerosis
(ALS) has been the lack of robust biomarkers for use as clinical trial endpoints …